|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-3-4
|
|
pubmed:abstractText |
It is likely that there are some discrepancies in the safety and efficacy results for anticancer agents between those shown in registration studies for approval and those shown in clinical practice after market release. The aim of this survey was to confirm the safety and efficacy of S-1 for advanced gastric cancer after market release.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1436-3291
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6-11
|
|
pubmed:dateRevised |
2007-1-8
|
|
pubmed:meshHeading |
pubmed-meshheading:15747168-Aged,
pubmed-meshheading:15747168-Antimetabolites, Antineoplastic,
pubmed-meshheading:15747168-Creatinine,
pubmed-meshheading:15747168-Drug Combinations,
pubmed-meshheading:15747168-Female,
pubmed-meshheading:15747168-Health Surveys,
pubmed-meshheading:15747168-Humans,
pubmed-meshheading:15747168-Japan,
pubmed-meshheading:15747168-Male,
pubmed-meshheading:15747168-Middle Aged,
pubmed-meshheading:15747168-Oxonic Acid,
pubmed-meshheading:15747168-Product Surveillance, Postmarketing,
pubmed-meshheading:15747168-Pyridines,
pubmed-meshheading:15747168-Stomach Neoplasms,
pubmed-meshheading:15747168-Tegafur
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer.
|
|
pubmed:affiliation |
Division of Digestive Endoscopy/Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
